A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

BACKGROUND: Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a lower dose of AmBisome...

Descripción completa

Detalles Bibliográficos
Autores principales: Diro, Ermias, Blesson, Severine, Edwards, Tansy, Ritmeijer, Koert, Fikre, Helina, Admassu, Henok, Kibret, Aderajew, Ellis, Sally J., Bardonneau, Clelia, Zijlstra, Eduard E., Soipei, Peninah, Mutinda, Brian, Omollo, Raymond, Kimutai, Robert, Omwalo, Gabriel, Wasunna, Monique, Tadesse, Fentahun, Alves, Fabiana, Strub-Wourgaft, Nathalie, Hailu, Asrat, Alexander, Neal, Alvar, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336227/
https://www.ncbi.nlm.nih.gov/pubmed/30653490
http://dx.doi.org/10.1371/journal.pntd.0006988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336227/
https://www.ncbi.nlm.nih.gov/pubmed/30653490
http://dx.doi.org/10.1371/journal.pntd.0006988

Ejemplares similares